Mineralisation defects with pamidronate therapy for Paget's disease.
Bone biopsy samples were taken from 20 patients with Paget's disease before and after intravenous pamidronate therapy. In 10 patients given 180 or 360 mg during 6 or 9 weeks, bone turnover decreased as measured biochemically and histologically, but osteomalacia developed in 1 patient and mineralisation defects in 3. 10 other patients received 45 mg every 3 months for 1 year. Bone turnover decreased biochemically but not histologically, and osteoid thickness increased, suggesting impaired mineralisation. Despite overall efficacy, pamidronate has a narrow therapeutic range between resorption inhibition and mineralisation defects. Short courses given to achieve biochemical remission should be administered with caution.
Adamson
B B
BB
University Department of Pathology, Royal Infirmary, Glasgow, UK.
Gallacher
S J
SJ
Byars
J
J
Ralston
S H
SH
Boyle
I T
IT
Boyce
B F
BF
D002113:Calcification, Physiologic; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D010001:Osteitis Deformans / Q000188:drug therapy* / Q000378:metabolism; D010018:Osteomalacia / Q000139:chemically induced; D000077268:Pamidronate
D004164:Diphosphonates; D000077268:Pamidronate